Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Gains Rights to Agilent's Big Blue Cell Lines, Colonies

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that its BioReliance business has signed an agreement to acquire colonies and cell lines for toxicology testing from Agilent Technologies.

The deal covers colonies required for Agilent's Big Blue transgenic rodent mutation assay, which are in vivo genetic toxicology assays that measure mutation frequency in tissue. BioReliance will now own the Big Blue mutation models and will be the exclusive supplier of testing services based on the model.

Sigma-Aldrich also said that BioReliance is in the process of requalifying the assay to meet new regulatory requirements. It expects the Big Blue testing services to be commercially available in the second half of this year.

Financial and other terms of the agreement were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.